Update: Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies?

Gerald L Denardo, Sally J. DeNardo, Rod Balhorn

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.

Original languageEnglish (US)
Pages (from-to)383-397
Number of pages15
JournalCancer Biotherapy and Radiopharmaceuticals
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2008

Fingerprint

Radioimmunotherapy
Lymphoma
Radiotherapy
Radioisotopes
Non-Hodgkin's Lymphoma
Drug Combinations
Neoplasms
Molecular Targeted Therapy
B-Cell Lymphoma
Pharmaceutical Preparations

Keywords

  • Antibody
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy
  • Radionuclide
  • Radiotherapy
  • Solid cancers

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)
  • Oncology
  • Pharmacology

Cite this

Update : Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies? / Denardo, Gerald L; DeNardo, Sally J.; Balhorn, Rod.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 23, No. 4, 01.08.2008, p. 383-397.

Research output: Contribution to journalReview article

@article{6ef444dc56d149c6acea2c3000157ecf,
title = "Update: Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies?",
abstract = "The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.",
keywords = "Antibody, Non-Hodgkin's lymphoma, Radioimmunotherapy, Radionuclide, Radiotherapy, Solid cancers",
author = "Denardo, {Gerald L} and DeNardo, {Sally J.} and Rod Balhorn",
year = "2008",
month = "8",
day = "1",
doi = "10.1089/cbr.2007.0523-U",
language = "English (US)",
volume = "23",
pages = "383--397",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Update

T2 - Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies?

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

AU - Balhorn, Rod

PY - 2008/8/1

Y1 - 2008/8/1

N2 - The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.

AB - The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.

KW - Antibody

KW - Non-Hodgkin's lymphoma

KW - Radioimmunotherapy

KW - Radionuclide

KW - Radiotherapy

KW - Solid cancers

UR - http://www.scopus.com/inward/record.url?scp=51349133618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349133618&partnerID=8YFLogxK

U2 - 10.1089/cbr.2007.0523-U

DO - 10.1089/cbr.2007.0523-U

M3 - Review article

C2 - 18771343

AN - SCOPUS:51349133618

VL - 23

SP - 383

EP - 397

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -